tetano
Editor, Senior Moderator
Clin Case Rep
. 2022 Feb 2;10(2):e05323.
doi: 10.1002/ccr3.5323. eCollection 2022 Feb.
COVID-19 vaccine-related new-onset lichen planus
Arefeh Babazadeh[SUP] 1 [/SUP], Ronak Miladi[SUP] 2 [/SUP], Mohammad Barary[SUP] 3 4 [/SUP], Maria Shirvani[SUP] 2 [/SUP], Soheil Ebrahimpour[SUP] 1 [/SUP], Zeinab Aryanian[SUP] 5 6 [/SUP], Zeinab Mohseni Afshar[SUP] 2 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) vaccines significantly impacted world health and well-being. However, various adverse events have been observed following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Cutaneous reactions have been prevalent following many vaccines, including COVID-19 vaccines. Here, we present a case of new-onset lichen planus in a patient who received the COVID-19 vaccine at the same time as being infected with SARS-CoV-2. A 52-year-old woman presented to the clinic with extensive pruritic skin lesions. The eruptions had appeared a week after her second dose of the Sinopharm COVID-19 vaccine. She mentioned a history of SARS-CoV-2 infection approximately 10 days following the first dose of her vaccine, causing a 1-month delay in getting the second dose. Her past medical history was not significant. On examination, erythematous and squamous papules were demonstrated predominantly on the extremities, including inguinal and axillary folds. Moreover, desquamation of the lips was visible, and buccal lesions were also found. After consultation with a dermatologist, a skin biopsy was indicated for the patient, but she refused to undergo the procedure. Therefore, considering the typical appearance of the eruptions, lichen planus was suspected, for which she was treated with oral antihistamines and topical corticosteroids.
Keywords: COVID‐19; SARS‐CoV‐2; dermatology; lichen planus.
. 2022 Feb 2;10(2):e05323.
doi: 10.1002/ccr3.5323. eCollection 2022 Feb.
COVID-19 vaccine-related new-onset lichen planus
Arefeh Babazadeh[SUP] 1 [/SUP], Ronak Miladi[SUP] 2 [/SUP], Mohammad Barary[SUP] 3 4 [/SUP], Maria Shirvani[SUP] 2 [/SUP], Soheil Ebrahimpour[SUP] 1 [/SUP], Zeinab Aryanian[SUP] 5 6 [/SUP], Zeinab Mohseni Afshar[SUP] 2 [/SUP]
Affiliations
- PMID: 35140945
- PMCID: PMC8810943
- DOI: 10.1002/ccr3.5323
Abstract
Coronavirus disease 2019 (COVID-19) vaccines significantly impacted world health and well-being. However, various adverse events have been observed following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Cutaneous reactions have been prevalent following many vaccines, including COVID-19 vaccines. Here, we present a case of new-onset lichen planus in a patient who received the COVID-19 vaccine at the same time as being infected with SARS-CoV-2. A 52-year-old woman presented to the clinic with extensive pruritic skin lesions. The eruptions had appeared a week after her second dose of the Sinopharm COVID-19 vaccine. She mentioned a history of SARS-CoV-2 infection approximately 10 days following the first dose of her vaccine, causing a 1-month delay in getting the second dose. Her past medical history was not significant. On examination, erythematous and squamous papules were demonstrated predominantly on the extremities, including inguinal and axillary folds. Moreover, desquamation of the lips was visible, and buccal lesions were also found. After consultation with a dermatologist, a skin biopsy was indicated for the patient, but she refused to undergo the procedure. Therefore, considering the typical appearance of the eruptions, lichen planus was suspected, for which she was treated with oral antihistamines and topical corticosteroids.
Keywords: COVID‐19; SARS‐CoV‐2; dermatology; lichen planus.